ライフサイエンスコーパス: vasopressin

1 tic nucleus (SON; which secrete oxytocin and vasopressin).

2 fy genes whose transcription is regulated by vasopressin.

3 havior following the binding of its agonist, vasopressin.

4 s for gastrin-releasing peptide and arginine vasopressin.

5 al states that are modulated by oxytocin and vasopressin.

6 n of Y-27632 reverted the hyperreactivity to vasopressin.

7 ccelerates its endocytosis in the absence of vasopressin.

8 relationship with the neuropeptide modulator vasopressin.

9 melanin-concentrating hormone, oxytocin, and vasopressin.

10 al ganglion cells expresses the neuropeptide vasopressin.

11 Concealed vasopressin (0.03 U/min.) or norepinephrine infusions.

12 Arginine vasopressin (100 and 500 pm) and the PKC activator phorb

13 ly led to a low single digit nanomolar human vasopressin 1a (hV1a) receptor antagonist 38.

14 of intranasal administration of an arginine vasopressin 1A and 1B receptor agonist against 1) no tre

15 The vasopressin 1a receptor (V1aR) has been shown to have a

16 We therefore tested whether vasopressin 1a receptor (V1aR) inhibition would suppress

17 en behavioral variation and variation in the vasopressin 1a receptor gene (Avpr1a) in bonobos.

18 hisms in the genes encoding the oxytocin and vasopressin 1a receptors influence social memory for fac

19 sin can activate the HPA axis by stimulating vasopressin 1b (V1b) receptors located on the pituitary.

20 A2 area of the hippocampus, particularly the vasopressin 1b receptor (Avpr1b) expressed there, is nec

21 The vasopressin 1b receptor (Avpr1b) is critical for social

22 ment of the GHSR1a C-tail by the tail of the vasopressin 2 receptor greatly stabilizes them, producin

23 Blockade of the vasopressin-2 receptor (V2R) in the kidney has recently

24 The oral vasopressin-2 receptor antagonist tolvaptan causes aquar

25 A member of this class, the oral vasopressin-2 receptor antagonist tolvaptan, provides be

26 that resembles binding of the phosphorylated vasopressin-2 receptor tail to beta-arrestin-1.

27 Vasopressin (3, 10, and 30 pmol/kg, IV) produced increas

28 s also controls IRAP targeting and regulates vasopressin action in vivo.

29 Furthermore, the effect of IRAP to reduce vasopressin activity is a physiologically important cons

30 P2 water channels was reduced, implying that vasopressin activity is decreased.

31 These activations weakened with oxytocin and vasopressin administration such that neural responses to

32 Vasopressin agonists boosted placebo effects in women bu

33 Terlipressin is a synthetic vasopressin analogue that acts, via vascular vasopressin

34 ECV transfer and report that desmopressin, a vasopressin analogue, stimulated the uptake of fluoresce

35 cumulation was partially reduced by arginine vasopressin and almost completely blocked by selepressin

36 Vasopressin and corticosteroids are both commonly used a

37 We aimed to test for an interaction between vasopressin and corticosteroids in septic shock.

38 roved outcomes in patients treated with both vasopressin and corticosteroids.

39 ich when activated result in elevated plasma vasopressin and corticosterone.

40 The neuropeptides vasopressin and corticotropin-releasing factor facilitat

41 controlled by the pituitary hormone arginine vasopressin and defective trafficking results in nephrog

42 Plasma vasopressin and ghrelin were measured in response to the

43 VAS scores correlated positively with plasma vasopressin and left inferior frontal and middle occipit

44 us adverse events associated with the use of vasopressin and norepinephrine are not clear.

45 Serious adverse events associated with vasopressin and norepinephrine in patients who have sept

46 The opposite modulation of their output by vasopressin and oxytocin could thus create a dynamic equ

47 Both vasopressin and oxytocin modulate brain regions involved

48 lopment of various subcortical regions where vasopressin and oxytocin receptors are adjacently expres

49 mic preoptic area including those expressing vasopressin and oxytocin.

50 NCs, leading to a decrease in the release of vasopressin and oxytocin.

51 to 0.06 U/min) and hydrocortisone (n = 101), vasopressin and placebo (n = 104), norepinephrine and hy

52 ts occurred in 10.5% and 9.7% of patients in Vasopressin and Septic Shock trial and St. Paul's Hospit

53 ratio, 1.89; 95% CI, 1.26-2.85; p = 0.002 in Vasopressin and Septic Shock trial and St. Paul's Hospit

54 In the Vasopressin and Septic Shock Trial cohort, rs315952C ass

55 In the Vasopressin and Septic Shock Trial cohort, we performed

56 are differences in plasma cytokine levels in Vasopressin and Septic Shock Trial for lactate less than

57 pinephrine group 28- and 90-day mortality in Vasopressin and Septic Shock Trial in lactate subgroups.

58 rates were 10-12 % higher than the original Vasopressin and Septic Shock Trial mortality.

59 essin versus norepinephrine and mortality in Vasopressin and Septic Shock Trial.

60 mutant and wild-type mice had similar plasma vasopressin and solute excretion levels.

61 Many SCN neurons express vasopressin, and it has been assumed that the role of va

62 a potential clinically important benefit for vasopressin, and larger trials may be warranted to asses

63 dullin, CT-pro-endothelin-1, CT-pro-arginine vasopressin, and MR-pro-atrial natriuretic peptide), alo

64 unctions, abnormalities in central oxytocin, vasopressin, and serotonin neurotransmission, and neuroi

65 in 1776 patients enrolled in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study Wi

66 oc analysis was performed of the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study w

67 a early in patients selected for an enhanced vasopressin antagonism response.

68 fraction </=40% enrolled in the Efficacy of Vasopressin Antagonist in Heart Failure Outcome Study wi

69 synthesis of nonpeptide orally bioavailable vasopressin antagonists devoid of agonistic activity (va

70 Vasopressin antagonists, which promote low water permeab

71 new strategy may be utilization of aquaretic vasopressin antagonists.

72 The neuropeptides oxytocin and vasopressin are evolutionarily conserved regulators of s

73 The related neuropeptides oxytocin and vasopressin are involved in species-typical behavior, in

74 the endogenous IRAP substrates oxytocin and vasopressin are known to facilitate learning and memory.

75 Oxytocin and vasopressin are thus important for the development of a

76 Two peptide hormones, oxytocin and vasopressin, are also associated with autism and genes e

77 ributing to those differences and identified vasopressin as a regulator of nestbuilding behaviour.

78 eded to assess the clinical effectiveness of vasopressin as the initial vasopressor therapy with or w

79 esearch due to the therapeutic potentials of vasopressin as well as the possibility to systematically

80 dications in volume-overload edemas and high-vasopressin-associated hyponatremias.

81 we report that serotonin (5-HT) and arginine-vasopressin (AVP) act in opposite ways in the hypothalam

82 olocalization with the neuropeptide arginine vasopressin (AVP) and clock proteins (PER2 and BMAL1), s

83 nse to the neurohypophyseal hormone arginine vasopressin (AVP) and in the expression of oxidative str

84 The neuropeptides vasopressin (AVP) and oxytocin (OT) have been implicated

85 Oxytocin (OT) and arginine vasopressin (AVP) are two small, related neuropeptide ho

86 s was dependent on the neuropeptide arginine vasopressin (AVP) because it was prevented by pharmacolo

87 Arginine vasopressin (AVP) has a key role in osmoregulation by fa

88 Prior studies show that oxytocin (Oxt) and vasopressin (Avp) have opposing actions on the skeleton

89 nthesis of the antidiuretic hormone arginine vasopressin (AVP) increases in the hypothalamus, and thi

90 Arginine vasopressin (AVP) is a neurohypophysial hormone regulati

91 accompanied by elevated circulating arginine vasopressin (AVP) levels in SHR-A3 compared with SHR-B2.

92 of the SCN, including VIP, GRP, and arginine vasopressin (AVP) neurons, with each ipRGC innervating s

93 asmatic nucleus output neuropeptide arginine-vasopressin (AVP) on the activity of preoptic area kissp

94 The 99mTc-labeled conjugates of the vasopressin (AVP) peptide and of its analogue d(CH2)5[D-

95 Synthetic arginine vasopressin (AVP) receptor agonists able to induce syste

96 Arginine vasopressin (AVP) regulates fluid balance and blood pres

97 rallel increase in water intake and arginine vasopressin (AVP) secretion to promote fluid expansion a

98 Vasopressin (AVP) signaling via PKA and other kinases ac

99 Arginine vasopressin (AVP) stimulates the release of enteroendocr

100 trophin-releasing hormone (CRH) and arginine vasopressin (AVP) to control the release of adrenocortic

101 trophin-releasing hormone (CRH) and arginine vasopressin (AVP) to control the release of adrenocortic

102 iciency of the antidiuretic hormone arginine vasopressin (AVP) underlies diabetes insipidus, which is

103 al three distinct binding sites for arginine vasopressin (AVP) within its V2 -receptor (V2 R).

104 Here we show that arginine vasopressin (AVP), a neuropeptide that mediates complex

105 ncy and preschool, assayed oxytocin (OT) and vasopressin (AVP), and measured coparenting and child be

106 osmolality and serum sodium, plasma arginine vasopressin (AVP), and plasma copeptin concentrations fr

107 water reabsorption is controlled by arginine vasopressin (AVP), which binds to V2 receptors, resultin

108 ause cAMP is a central modulator of arginine vasopressin (AVP)-induced water transport in the renal c

109 PDE4 caused a greater increase in basal and vasopressin (AVP)-stimulated cAMP levels and Cl(-) secre

110 elease of the neuropeptide hormone, arginine vasopressin (AVP).

111 rcuits that relay stress information include vasopressin- (AVP) and oxytocin- (OC) containing neurons

112 tor/vasopressin V2 receptor agonist arginine vasopressin because of its lack of agonist activity at t

113 first study that demonstrates that arginine vasopressin boosts placebo effects and that the effect o

114 Vasopressin can activate the HPA axis by stimulating vas

115 Vasopressin cannot correct paracellular water loss in Il

116 Arginine vasopressin colocalized with EGFP more often in females

117 g adults with septic shock, the early use of vasopressin compared with norepinephrine did not improve

118 s no difference in the area under the plasma vasopressin concentration curve between patients with an

119 gnetic resonance imaging, and serum arginine vasopressin concentration) were compatible with a diagno

120 Plasma vasopressin concentrations were measured at baseline, 6

121 The results suggest that the novel vasopressin conjugate 99mTc(NS3)(CN-AVP(an)) is a desira

122 in-concentrating hormone, oxytocin, arginine vasopressin, corticotropin-releasing hormone (CRH) or th

123 In response to 1-desamino-8-D-arginine vasopressin (DDAVP), peak VWF:Ag levels exceeded 100 IU/

124 idiuresis produced by 1-deamino-8-D-arginine vasopressin (DDAVP).

125 To compensate for accelerated vasopressin degradation, vasopressin secretion was incre

126 controls AQP2 apical membrane abundance in a vasopressin-dependent manner, allowing for urine volume

127 oosts placebo effects and that the effect of vasopressin depends upon a significant sex by treatment

128 1-deamino-8-d-arginine vasopressin (desmopressin [DDAVP]) is clinically efficac

129 din E2 (PGE2), cholecystokinin 8 (CCK8), and vasopressin displayed an increase of Vmax and a variable

130 The activity of oxytocin and vasopressin during development should inform our underst

131 ate, plasma concentration of catecholamines, vasopressin, endothelin, and renin activity in 14 patien

132 ng mechanisms and subsequent deregulation of vasopressin excretion by the neurohypophysis.

133 The MRP2 substrates CCK8 and vasopressin exhibited Michaelis-Menten kinetics independ

134 Genetic inhibition of vasopressin expression or treatment with a pharmacologic

135 ong evidence suggests that certain hormones (vasopressin), foods (fructose), and metabolic products (

136 we discuss how the evolution of oxytocin and vasopressin from a single ancestor peptide after gene du

137 iased modulation is mediated by oxytocin and vasopressin G-protein-coupled receptors.

138 (interquartile range [IQR], 1 to -24) in the vasopressin group and 13 days (IQR, 1 to -25) in the nor

139 ailure was 94 of 165 patients (57.0%) in the vasopressin group and 93 of 157 patients (59.2%) in the

140 less use of renal replacement therapy in the vasopressin group than in the norepinephrine group (25.4

141 s (10.7%) had a serious adverse event in the vasopressin group vs 17 of 204 patients (8.3%) in the no

142 The neuropeptide vasopressin has an important role in this entrainment.

143 Thirty-one patients were allocated to vasopressin + hydrocortisone and 30 patients to vasopres

144 in the maintenance of the pressor effects of vasopressin in endotoxemic rats.

145 o-kinase potentiates the vascular effects of vasopressin in the kidneys, contributing to the maintena

146 as implicated the neuropeptides oxytocin and vasopressin in the modulation of human neural activity u

147 in, and it has been assumed that the role of vasopressin in the SCN reflects the activity of these ce

148 We have discovered that vasopressin-independent facets of this homeostatic mecha

149 Vasopressin-induced aquaporin-2 phosphorylation within t

150 xiety and cortisol levels showed the largest vasopressin-induced modulation of placebo effects, sugge

151 ICU patients with septic shock who received vasopressin infusion added to at least one concomitant v

152 yscus and chemogenetics in Mus, we show that vasopressin inhibits nest building but not other parenta

153 ollecting duct; is modulated in abundance by vasopressin; interacts with aquaporin-2 (AQP2), Hsp70, a

154 Here we show that vasopressin is also expressed in many retinal cells that

155 d to differences in nest-building behaviour, vasopressin is differentially expressed in the hypothala

156 pig neonate demonstrated that the effect of vasopressin is not dependent on the level of maturation

157 Initial vasopressin IV infusion titrated up to 0.06 U/min and th

158 between these drugs, with higher circulating vasopressin levels and improved outcomes in patients tre

159 Vasopressin levels begin to fall within minutes of water

160 Plasma vasopressin levels were measured at 6-12 and 24-36 hours

161 Plasma vasopressin levels were not higher in the hydrocortisone

162 essor genotype pathway polymorphisms, plasma vasopressin levels, and serious adverse events.

163 of septic shock, but it did not alter plasma vasopressin levels.

164 own insect neuropeptides except for arginine-vasopressin-like peptide (AVLP), CNMamide, neuropeptide-

165 Vasopressin lowered mortality versus norepinephrine if l

166 twork describing PKA signaling that explains vasopressin-mediated regulation of membrane trafficking

167 Vasopressin-mediated regulation of renal water excretion

168 r genes, consistent with the conclusion that vasopressin-mediated transcriptional regulation is highl

169 multidisciplinary approach, we investigated vasopressin-mediated vascular responses in SON arteriole

170 Oxytocin and vasopressin modulate a range of species typical behavior

171 e how intranasally administered oxytocin and vasopressin modulated neural activity when receiving neg

172 We localized a subpopulation of excitatory vasopressin neurons in the anterior hypothalamus that ma

173 nts of genetically identified neuroendocrine vasopressin neurons show they can anticipate osmotic cha

174 The effects of vasopressin on expectancy-induced analgesia were signifi

175 The effects of vasopressin on isolated aortic rings, cardiac function,

176 h Y-27632 partially inhibited the effects of vasopressin on mean arterial pressure and significantly

177 The effect of vasopressin on mean arterial pressure was unaltered and

178 sing; however, the influence of oxytocin and vasopressin on neural activity elicited during negative

179 ure and significantly reduced the effects of vasopressin on renal blood flow in control but not in en

180 ur results show effects of both oxytocin and vasopressin on the brain network involved in negative so

181 ess than or equal to 2 mmol/L, randomized to vasopressin or norepinephrine.

182 eleasing hormone and do not express arginine vasopressin or oxytocin.

183 dditional continuous IV infusion of arginine vasopressin or selepressin was titrated to raise and mai

184 responses were provoked by stimulation with vasopressin or serum.

185 s oxytocin, corticotropin-releasing hormone, vasopressin, or prodynorphin.

186 We isolated the insect oxytocin/vasopressin orthologue inotocin from the black garden an

187 ntagonism acting on loci within the arginine vasopressin-oxytocin pathway explains how genetic divers

188 ted to gain novel insights into the oxytocin/vasopressin peptide-receptor interaction, which led to t

189 opressin + hydrocortisone and 30 patients to vasopressin + placebo.

190 Copeptin is a stable arginine vasopressin precursor associated with increased risk of

191 for the clearance of misfolded pro-arginine vasopressin (proAVP) in the ER.

192 ne group) and required a lower total dose of vasopressin (ratio, 0.47; 95% CI, 0.32-0.71) compared wi

193 Among monogamous prairie voles, levels of vasopressin receptor (encoded by the gene avpr1a) in bra

194 Reciprocally, Gs enhances IP1 through vasopressin receptor (V1A-R) but not alpha1 adrenergic r

195 tissues through the inhibition of the type-2 vasopressin receptor (V2R) constitutes a validated strat

196 Here we demonstrate that a vasopressin receptor (V2R) mutant with truncated third i

197 Expression of arginine vasopressin receptor 1a (Avpr1a) and oxytocin receptor (

198 ingle 20 mg intravenous dose of the arginine vasopressin receptor 1A (V1a) antagonist, RG7713, on exp

199 le-nucleotide polymorphism near the arginine vasopressin receptor 1b gene is associated with serious

200 n of STAT3 in renal cystic cells depended on vasopressin receptor 2 (V2R) signaling, which increased

201 treatment of mpkCCD14 cells with the type 2 vasopressin receptor agonist dDAVP increased mRNA and pr

202 Vasopressin receptor antagonists, urea, and loop diureti

203 ein, the oxytocin receptor, and the arginine vasopressin receptor contain VDREs for activation.

204 e value in testing medications targeting the vasopressin receptor in high stress, alcohol-dependent p

205 selected for greater potential benefit from vasopressin receptor inhibition, tolvaptan was not assoc

206 n important role for development of oxytocin/vasopressin receptor modulators that would enable clear

207 ace levels of two folding-defective human V2-vasopressin receptor mutants, which were susceptible to

208 has made possible the selective blockade of vasopressin receptor subtypes for therapeutic purposes.

209 First, the vasopressin receptor-2 agonist, dDAVP, was delivered to

210 lial cells expressing the Galphas-coupled V2 vasopressin receptor.

211 ectivity versus the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31 (

212 Vasopressin receptors appear to have a regulatory role i

213 nM, selectivity ratios versus related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM,

214 zation of the parathyroid hormone and type 2 vasopressin receptors.

215 properties on the insect and human oxytocin/vasopressin receptors.

216 d by transmembrane water fluxes augmented by vasopressin-regulated aquaporin-4 (AQP4).

217 Vasopressin-regulated expression and insertion of aquapo

218 The analysis revealed only 35 vasopressin-regulated genes (of 3659) including Aqp2.

219 These data are consistent with vasopressin-regulated uptake of ECVs in vivo We conclude

220 Aquaporin-2 (AQP2) is the vasopressin-regulated water channel that controls renal

221 Vasopressin regulates phosphorylation at four sites with

222 Light-evoked vasopressin release contributes to the responses of SCN

223 Light-induced vasopressin release enhances the responses of SCN neuron

224 We observed that vasopressin release from the SCN decreases the temperatu

225 sepsis features impaired thirst and enhanced vasopressin release, the basis for these defects is unkn

226 nabled a distinctive regulation of pituitary vasopressin release.

227 portance of IRAP translocation to inactivate vasopressin remains uncertain.

228 Hydrocortisone spared vasopressin requirements, reduced duration, and reduced

229 which increases histone H3K27 acetylation of vasopressin-responsive genes (confirmed by ChIP-seq).

230 otic stress, posterior pituitary-projecting, vasopressin-secreting neurons (VPpp neurons) counter osm

231 tinct cellular processes to regulate thirst, vasopressin secretion and autonomic function.

232 xtracellular osmolarity stimulate thirst and vasopressin secretion through a central osmoreceptor; ho

233 ate for accelerated vasopressin degradation, vasopressin secretion was increased, as assessed by the

234 other osmolytes readily stimulate thirst and vasopressin secretion.

235 Alternatives such as vasopressin/selepressin, angiotensin II, and phenylephri

236 In contrast, vasopressin, serotonin, and testosterone play only limit

237 ted roles of V2R signaling and suggests that vasopressin signaling itself may contribute crucially to

238 n mouse collecting duct cells to ask whether vasopressin signaling selectively increases Aqp2 gene tr

239 ice to discover an important contribution of vasopressin signaling to the evolution of nest building.

240 -like 3 by PKC or PKA downstream of AngII or vasopressin signaling, respectively, abrogates binding.

241 rvation of the 600-million-year-old oxytocin/vasopressin signalling system.

242 Here, we show that arginine vasopressin specifically activates interneurons to suppr

243 level in wild-type mice but does not restore vasopressin-stimulated levels of urea permeability.

244 model predicts that, through PKA activation, vasopressin stimulates AQP2 exocytosis by inhibiting MAP

245 also predicts that, through PKA activation, vasopressin stimulates Aqp2 transcription through induct

246 Since vasopressin stimulates renal water and sodium reabsorpti

247 was similar to levels in wild-type mice, but vasopressin stimulation of urea permeability in wild-typ

248 thin the domain of social communication, the vasopressin system is implicated in social cognition and

249 o effects by targeting pharmacologically the vasopressin system, characterized by a sexually dimorphi

250 ease of cross-reactivity with its correlated vasopressin system.

251 We used optogenetics to excite vasopressin terminals, originating from the hypothalamic

252 ultured cells that indicates aldosterone and vasopressin, the two major hormones regulating sodium re

253 rtisone group required a shorter duration of vasopressin therapy (3.1 d; 95% CI, 1.1-5.1; shorter in

254 Patients were randomly allocated to vasopressin (titrated up to 0.06 U/min) and hydrocortiso

255 ounts for the ability of the peptide hormone vasopressin to regulate water excretion via a phosphoryl

256 ugh these findings do not support the use of vasopressin to replace norepinephrine as initial treatme

257 We compared vasopressin-to-norepinephrine group 28- and 90-day morta

258 ctivity of the net transcriptional response, vasopressin treatment was associated with increased RNA

259 d accumulation to levels similar to arginine vasopressin treatment.

260 Resuscitation with the selective vasopressin type 1a receptor agonist selepressin blocked

261 ascular leak more effectively than the mixed vasopressin type 1a receptor/vasopressin V2 receptor ago

262 r fused to the carboxyl-terminal tail of the vasopressin type 2 receptor was nearly irreversible.

263 interact with beta-arrestins, such as type-2 vasopressin, type-1 angiotensin, and CXC type-4 chemokin

264 vasopressor in septic shock; however, early vasopressin use has been proposed as an alternative.

265 Early vasopressin use was well tolerated with only one serious

266 vasopressin analogue that acts, via vascular vasopressin V1 receptors, as a systemic vasoconstrictor.

267 olished by pretreatment of the RVLM with the vasopressin V1a receptor antagonist, SR 49059 (-1 +/- 1

268 t vascular tone through interaction with the vasopressin V1a receptor but that [Pyr(1) ]apelin-13-ind

269 activated the insect inotocin and the human vasopressin V1b receptors, but inhibited the human V1aR.

270 iven fluid secretion (PDE3), and response to vasopressin V2 receptor activation (both).

271 than the mixed vasopressin type 1a receptor/vasopressin V2 receptor agonist arginine vasopressin bec

272 treatment of selepressin with the selective vasopressin V2 receptor agonist desmopressin were simila

273 mice before and after administration of the vasopressin V2 receptor antagonist tolvaptan.

274 cause of its lack of agonist activity at the vasopressin V2 receptor.

275 Vaptans acting on the vasopressin V2 receptors (aquaretics) have attracted att

276 beta2-adrenergic, angiotensin II type 1 and vasopressin V2 receptors was altered by the beta-arresti

277 atinine clearance, >/=60 ml per minute), the vasopressin V2-receptor antagonist tolvaptan slowed the

278 definition (lactate > 2 mmol/L) differ from vasopressin versus norepinephrine and mortality in Vasop

279 Our first hypothesis was that the vasopressin versus norepinephrine comparison and 28-day

280 gnificantly (p = 0.028) lower mortality with vasopressin versus norepinephrine in lactate less than o

281 y and control the synthesis and secretion of vasopressin (VP) and oxytocin (OT) by the neurohypophysi

282 The magnocellular vasopressin (VP) and oxytocin (OT) neurones undergo long

283 with salt intake and thus promote release of vasopressin (VP) from the neurohypophysis.

284 units (alpha, beta and gamma) are located in vasopressin (VP) magnocellular neurons in the hypothalam

285 Because vasopressin (VP) neurons play a pivotal role in coordina

286 s insipidus (NDI) is caused by impairment of vasopressin (VP) receptor type 2 signaling.

287 nd voles bind not only forms of OT, but also vasopressin (VP), and >10 cell groups produce each pepti

288 endritic release of neuropeptides, including vasopressin (VP), constitutes a key signaling modality i

289 the secretion of the osmoregulatory hormone vasopressin (VP), linking nutritional status to the cont

290 ABSTRACT: Oxytocin (OT)- and vasopressin (VP)-secreting magnocellular neurons of the

291 than in the norepinephrine group (25.4% for vasopressin vs 35.3% for norepinephrine; difference, -9.

292 -kinase in the renal and systemic effects of vasopressin was investigated through administration of t

293 gned to mimic the N terminus of oxytocin and vasopressin, were assessed and compared based on their a

294 ased on norepinephrine equivalents excluding vasopressin, were significantly lower at 24 hours in the

295 c perturbations by altering their release of vasopressin, which controls renal water excretion.

296 A substrate of IRAP is vasopressin, which controls water homeostasis.

297 Vasopressin, which is a nonapeptide with substantial str

298 tem inhibitor therapy versus those receiving vasopressin who were not on chronic renin-angiotensin-al

299 pressure in septic shock patients receiving vasopressin who were on chronic renin-angiotensin-aldost

300 response in septic shock patients receiving vasopressin who were on chronic renin-angiotensin-aldost